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AbstrACt
Objective To investigate the demographic and clinical 
factors associated with antidepressant use for depressive 
disorder in a psychiatric healthcare setting using a 
retrospective cohort study design.
setting Data were extracted from a de-identified data 
resource sourced from the electronic health records 
of a London mental health service. Relative risk ratios 
(RRRs) were obtained from multinomial logistic regression 
analysis to ascertain the probability of receiving common 
antidepressant treatments relative to sertraline.
Participants Patients were included if they received 
mental healthcare and a diagnosis of depression with 
antidepressant treatment between March and August 2015 
and exposures were measured over the preceding 12 
months.
results Older age was associated with increased use of 
all antidepressants compared with sertraline, except for 
negative associations with fluoxetine (RRR 0.98; 95% CI 
0.96 to 0.98) and a combination of two selective serotonin 
reuptake inhibitors (SSRIs) (0.98; 95% CI 0.96 to 0.99), 
and no significant association with escitalopram. Male 
gender was associated with increased use of mirtazapine 
compared with sertraline (2.57; 95% CI 1.85 to 3.57). 
Previous antidepressant, antipsychotic and mood stabiliser 
use were associated with newer antidepressant use (ie, 
selective norepinephrine reuptake inhibitors, mirtazapine 
or a combination of both), while affective symptoms 
were associated with reduced use of citalopram (0.58; 
95% CI 0.27 to 0.83) and fluoxetine (0.42; 95% CI 0.22 
to 0.72) and somatic symptoms were associated with 
increased use of mirtazapine (1.60; 95% CI 1.00 to 2.75) 
relative to sertraline. In patients older than 25 years, past 
benzodiazepine use was associated with a combination 
of SSRIs (2.97; 95% CI 1.32 to 6.68), mirtazapine (1.94; 
95% CI 1.20 to 3.16) and venlafaxine (1.87; 95% CI 1.04 
to 3.34), while past suicide attempts were associated with 
increased use of fluoxetine (2.06; 95% CI 1.10 to 3.87) 
relative to sertraline.
Conclusion There were several factors associated with 
different antidepressant receipt in psychiatric healthcare. 
In patients aged >25, those on fluoxetine were more 
likely to have past suicide attempt, while past use of 
antidepressant and non-antidepressant use was also 
associated with use of new generation antidepressants, 
potentially reflecting perceived treatment resistance.
IntrOduCtIOn 
There are standard national guidelines 
directing antidepressant prescription in 
secondary care1 (secondary care refers to 
non-first-line treatment services provided by 
health professionals to patients who are usually 
referred by their primary care provider such 
as general practitioner). British guidelines for 
the management of depression in secondary 
care specify that care plans should involve, 
among other things, the development of a 
crisis plan that identifies and details manage-
ment of potential triggers for a depressive 
episode or a worsening of existing symp-
toms.1 However, in practice a range of patient 
and clinician characteristics may influence 
antidepressant prescription.1 2 For example, 
a community-based study of data collected 
from 10 psychiatrists who offered antidepres-
sant treatment to 1137 patients found that this 
strengths and limitations of this study
 ► To our knowledge, this is the first study profiling cor-
relates of antidepressant use in a cohort of patients 
receiving treatment in a mental health service set-
ting in the UK.
 ► The data included hard to measure variables such 
as depressive symptoms, derived using text mining 
algorithms.
 ► Focusing on antidepressant data in a 6-month win-
dow limited sample sizes for some analyses.
 ► The analysis is cross-sectional and causal relation-
ships cannot be inferred from associations observed.
 ► The duration of the antidepressant treatment before 
and during the observation period was not known.
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was influenced by avoidance of side effects, the presence 
of comorbidities and the presence of specific depressive 
symptoms such as anxiety, insomnia, fatigue, irritability 
or increased appetite.3 Supporting these results, studies 
profiling antidepressant prescriptions have established 
that patient–clinician relationships, past experiences with 
medication and patient symptoms can influence antide-
pressant prescription; however, to date these have been 
set in primary care.4–7
There are few studies investigating factors associated 
with antidepressant use in a secondary mental healthcare 
setting,8 9 where antidepressant use is common, although 
more frequently in cases where first-line treatment has 
been ineffective or is complex for other reasons.10 The 
limited availability of secondary mental healthcare 
(compared with primary care) data for research,11 12 has 
presented wider challenges for the identification of treat-
ment receipt and response,13 compounded by the limited 
availability of data on important clinical parameters such 
as depressive symptoms14 due to variation in clinical 
recording practices.15 Limited data availability can be 
countered by novel approaches to information extraction 
applied to health records databases. For example, natural 
language processing techniques are being introduced in 
psychiatric research to help with data extraction on varying 
levels.16 In a systematic review, Abbe et al16 identified 38 
studies using natural language processing techniques for 
psychiatry-related research, including analyses of patient 
perspectives on diagnosis and treatment, detecting diag-
nosis based on frequency of use of relevant terms, anal-
yses of medical literature and analyses of psychiatric 
clinical records. The review emphasised the potential 
value of text mining but also the unique challenges faced 
in this field, such as the mentions of emotions and subtle 
descriptions of personality or characteristics which may 
indicate symptomatology, the challenge of distinguishing 
of terms with multiple meanings and the requirement for 
very large training corpora to achieve robust results.
To the best of our knowledge, there has not been a 
study profiling antidepressant prescription in the UK, 
outside of primary care.17 18 The objective of our study 
was to investigate whether clinical symptoms (extracted 
with help of text mining techniques), past antidepressant 
or other psychotropic treatment or demographic factors 
are associated with different antidepressant treatment 
schedules used for depressive disorders in a secondary 
psychiatric healthcare setting.
MethOds
the dataset
The Clinical Record Interactive Search (CRIS) system 
provides de-identified case note information from the 
South London and Maudsley (SLaM) National Health 
Service Trust, a large mental healthcare provider serving 
a geographical catchment of approximately 1.3 million 
residents in four South London boroughs (Lambeth, 
Southwark, Lewisham and Croydon). Electronic health 
records have been used comprehensively across all SLaM 
services since 2006. CRIS was established in 2008 to allow 
searching and retrieval of de-identified19 clinical infor-
mation for research purposes within a robust, patient-led 
governance framework and currently houses records on 
over 270 000 cases.20 21 The system allows for retrieval of 
information from de-identified structured and free-text 
fields
Observation window and inclusion criteria
A 6-month interval from 1 March to 31 August 2015 was 
selected as the observation period where the type of anti-
depressant use, defined as single antidepressant use and 
antidepressants users on two antidepressants (referred to 
here as binary antidepressant use) represented the main 
dependent variable. All antidepressant use groups were 
mutually exclusive as described in the next section. Inde-
pendent variables (demographic and clinical variables) 
were extracted over the 12 months prior to the observa-
tion window and their associations with antidepressant 
use within the observation window were analysed.
Patients were included if they received active SLaM care 
within the 6-month observation interval, and if they had 
received any of the following clinical diagnoses according 
to 10th Revision of the International Classification of 
Diseases (ICD) codes on or before the 31 August 2015: 
depressive episode (F32), recurrent depressive disorder 
(F33), dysthymia (F34.1), and/or mixed anxiety and 
depression (F41.2). Individuals were excluded if they 
had received any F01–F09 (organic disorders), F20–F29 
(schizophrenia-like disorders) or F31 (bipolar disorder) 
diagnoses. Active care was defined as at least one face-
to-face contact with SLaM service within the observation 
window.
Antidepressant use
Antidepressant use was ascertained using an algorithm 
developed in General Architecture for Text Engineering 
(GATE) software,22 designed to extract data specifically 
on any medication recorded in free-text fields (eg, case 
notes, correspondence). Details of the development of 
this medication extraction algorithm have previously 
been published.14 21 For each patient in the final cohort, 
any antidepressant use (regardless of the duration of 
use) during the observation window was extracted as a 
binary variable. The antidepressants for which data were 
collected comprised the following: (1) tricyclic and tricy-
clic related—amitriptyline, clomipramine, dosulepin, 
doxepin, imipramine, lofepramine, nortriptyline, trim-
ipramine, mianserin and trazodone; (2) monoamine 
oxidase inhibitors isocarboxazid, phenelzine, tranylcypro-
mine and moclobemide; (3) selective serotonin reuptake 
inhibitors (SSRIs)—sertraline, fluoxetine, citalopram, 
escitalopram, fluvoxamine and paroxetine; (4) selec-
tive norepinephrine reuptake inhibitors (SNRIs)—
venlafaxine, reboxetine and duloxetine and (5) Other 
classes—agomelatine, bupropion and mirtazapine.
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The final cohort comprised 1561 patients. The most 
common mutually exclusive monotherapy antidepres-
sant used within the 6-month window was sertraline (360 
patients), followed by mirtazapine (305), citalopram 
(213), fluoxetine (200), venlafaxine (143), escitalopram 
(52). The most common mutually exclusive double 
antidepressant combinations were any one SSRI with 
mirtazapine (110), any one SNRI with mirtazapine (89) 
and a combination of any two SSRIs (89). Groups with no 
antidepressant use data (n=1936) were excluded, as were 
groups with less than 50 patients (to avoid small cell sizes) 
and those where algorithms indicated use of three or 
more antidepressants (n=494). All antidepressant groups 
were mutually exclusive.
Covariates
Apart from demographic variables, all other covariate 
data were extracted from data recorded within the 12 
months prior to the observation window. Demographic 
variables were extracted from structured fields, but all 
other data variables (listed below) were individually 
extracted using GATE and TextHunter, two text mining 
software tools which can be programmed to extract data 
from free-text notes via rules-based and machine learning 
techniques, respectively. All clinical symptom data vari-
ables were extracted using TextHunter.
Demographic variables
Ethnic group, age, gender, marital status were extracted 
from structured fields in the source record. Area-level 
deprivation was measured from the Index of Multiple 
Deprivation (IMD) that is derived from 2011 national 
Census data for each individual address, aggregated to 
Lower Super Output Areas—geographical units with a 
mean of 1500 inhabitants. The widely used IMD score 
combines Census-derived data across multiple domains 
(income, employment, health, education, barriers to 
housing/services, living environment, crime) and ranks 
each area at a national level.23
Diagnosis-derived depression severity
Based on the latest-recorded diagnostic code, depres-
sion severity was estimated in three categories—mild, 
moderate/severe and unspecified. Mild severity included 
diagnoses of F32.0 mild depressive episode, mild, F34.0 
recurrent depressive episode, mild, F34.1 dysthymia and 
F41.2 mixed anxiety and depressive disorders. Moderate 
to severe depressive severity included diagnoses of F32.1 
moderate depressive episode, F32.3 severe depressive 
episode with psychotic episode, F32.2 severe depres-
sion without psychotic episode, F33.1 recurrent depres-
sive episode, current episode moderate, F33.3 and 
F33.2, respectively, recurrent depressive episode with 
and without psychotic episode and F33.8 other recurrent 
depressive, unspecified. Unspecified severity was defined 
where there was no specified severity of depression within 
the ICD-code of depression, such as F32 depressive 
episode (unspecified severity), other depressive episodes, 
depressive episode, unspecified, F33 recurrent depressive 
disorder (unspecified severity), F33.4 recurrent depres-
sive in remission (unspecified severity).
Past medication/therapy use
Antipsychotic, benzodiazepine, mood stabiliser and anti-
depressant use in the preceding 12 months were ascer-
tained, as were the duration of the current treatment 
episode, any inpatient in the past 12 months, psycho-
therapy in the past 12 months and referral to improving 
access to psychiatric treatment (IAPT) services. IAPT 
services are a nationwide initiative introduced to increase 
access to psychological treatments for common mental 
disorders in primary care.
Clinical symptom data
As described, bespoke natural language processing algo-
rithms were applied to ascertain symptoms mentioned as 
present in text fields from the source electronic records. 
Data on 14 symptoms of depression were extracted on 
text fields from the preceding 12 months. To avoid small 
patient groups for analysis, depressive symptoms were 
categorised into subscales supported by previous results 
from confirmatory factor analysis on depression scale 
items (Beck Depressive Inventory-II) in a clinical psychi-
atric population24 and subsequently supported by other 
findings25 26 although with possible variation in factors at 
older ages.27 Hence the groupings were as follows: Cogni-
tive symptoms: helplessness, worthlessness and hopeless-
ness; Affective symptoms: anhedonia, poor motivation, 
apathy and low mood; Somatic symptoms: poor concen-
tration, agitation, irritability, low energy, insomnia, 
poor appetite and anergia. In addition, the presence of 
psychotic symptoms over the previous 12 months was 
ascertained from algorithms for hallucinations and delu-
sions. For these symptom groups, in order to minimise 
false positive occurrences, two or more mentions of symp-
toms in that domain were classified as a positive instance. 
Suicidal behaviour was ascertained over the preceding 12 
months using natural language processing algorithms for 
suicidal ideation and suicide attempt.
Patient and public involvement
Patients and public were not directly involved in this 
study, although all projects using the CRIS data resource 
are considered and approved by a patient-led oversight 
committee.19
statistical analysis
Group differences were analysed using χ2  tests for cate-
gorical variables, using t-tests or one-way analyses of vari-
ance for normally distributed continuous variables and 
using the Kruskal-Wallis test for non-normally distrib-
uted continuous data. Multinomial logistic regression 
analyses were used to answer the research question. The 
probability of receiving any of the common antidepres-
sant treatments relative to sertraline (the referent, most 
used, antidepressant category) was estimated using expo-
nentiated regression coefficients from the multinomial 
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regression which represents relative risk ratios (RRRs). To 
build a representative model of which correlates predict 
antidepressant use in secondary care, decisions to include 
variables in the final model were guided by the associa-
tion of each variable in an initial model including age and 
gender as covariates. Variables that did not have any signif-
icant associations in age-adjusted and gender- adjusted 
analysis were not included in the final model. For initial 
selection based on age-adjusted and gender-adjusted anal-
ysis, the significance was set at p≤0.25.28 This was to help 
minimise (1) exclusion of potentially key covariates and 
(2) inclusion of p<0.05 significant estimates occurring 
by chance. The selected variables were then simultane-
ously entered in a full model. In the fully adjusted model, 
significance level was set at p<0.05 for retaining variables. 
The correlates retained in the final multinomial regres-
sion model were age, gender, past inpatient status, past 
benzodiazepine use, past antipsychotic use, past mood 
stabiliser use, past antidepressant use, past psychotherapy 
and IAPT referrals, past experience of psychotic, somatic, 
affective and cognitive symptoms; and past experience of 
suicidal ideation and past suicide attempts. In addition, 
separate analysis was conducted in those aged 26 and 
over, on the assumption that different factors may be 
taken into consideration when considering prescriptions 
of antidepressants to children, adolescents and young 
people relative to adults.1 29
Any missing values were treated as null values in the 
analysis as they formed less than 5% of data. As part of 
sensitivity analysis, and to ensure important variables are 
not being excluded in the final model, a full multivariable 
model was analysed and any variables that were statistically 
and clinically non-significant were then removed from 
the model. The results from the final models (from the 
entire cohort analysis and the adult-only cohort) are avail-
able in online supplementary appendix for comparison.
results
Table 1 compares patient characteristics between patients 
using and not using antidepressants. Groups differed in 
age, ethnicity and deprivation with patients on antidepres-
sants being older, less deprived and of white background. 
Table 2 compares each antidepressant or antidepressant 
combination group by demographics, referral data, past 
medication use and past psychological therapy referral. 
The demographic and clinical differences between 
the antidepressant groups are statistically significant 
apart from ethnicity, area-level deprivation and having 
had a past referral for psychotherapy. Notably, patients 
receiving fluoxetine were younger, while older patients 
were over-represented in those receiving a combination 
of newer antidepressants such as mirtazapine and an 
SNRI; there were more males receiving mirtazapine than 
females; most of the antidepressant users were single, and 
only a minority had recorded non-antidepressant psycho-
tropic treatments or psychotherapy in the past. Table 3 
indicates that the majority of patients had a moderate to 
Table 1 Comparing characteristics between patients receiving or not receiving antidepressants during the 6-month evaluation 
period (n=3497)
Patient characteristics
On single or dual therapy 
antidepressants n=1561
Not on 
antidepressants n=1936
Gender
  Female 1229 1295 ᵡ2=0.07, df=1, p=0.80
  Male 706 759
Mean age 44.3 years 40.1 years t=−7.6, df=3908, p<0.001
Marital status
  Single 1091 (56.3%) 1302 (63.4%) ᵡ2=0.02, df=2, p=0.999
  Married 456 (23.5%) 319 (15.5%)
  Other 389 (20.0%) 434 (21.1%)
Area-level deprivation score tertile
  2.25–22.3 (least deprived) 631 (33.0%) 580 (28.7%) ᵡ2=9.1, df=2, p<0.05
  22.4–42.3 1099 (57.6%) 1224 (60.6%)
  42.4–62.3 (most deprived) 179 (9.4%) 215 (10.6%)
Ethnicity
  White 1220 (63.9%) 864 (42.1%) ᵡ2=10.5, df=1, p<0.01
  Other 716 (36.1%) 1191 (57.9%)
Depression severity from diagnosis
  Mild 383 (24.5%) 460 (28.3%) ᵡ2=0.007, df=2, p=0.99
  Moderate to severe 845 (54.1%) 845 (48.4%)
  Unspecified 333 (21.3%) 379 (23.3%)
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severe diagnosis of depression, a large majority of whom 
were not recorded as having experienced suicidal ideation 
or attempted suicide in the preceding 12 months. Apart 
from diagnostic severity and past psychotic symptoms, 
for all other past depressive symptoms and past suicidal 
ideation and attempts, the analysis indicated significant 
heterogeneity across the antidepressant user groups.
Tables 4 and 5 show the RRR, estimating the proba-
bility of patients being on any antidepressant relative to 
sertraline (the most common antidepressant received in 
our cohort), derived from the fully adjusted multinomial 
logistic regression models in the entire cohort and the 
adult-only cohort, respectively. Table 4 shows that relative 
to females, males are more likely to be on mirtazapine rela-
tive to sertraline. It also indicates that patients on newer 
antidepressants are more likely to have used non-antide-
pressant psychotropic medication or been on antidepres-
sants in the past. Those on citalopram or fluoxetine are 
less likely to have experienced affective symptoms (such 
as low mood and poor motivation) in the past compared 
with those on sertraline, while those who have experi-
enced somatic symptoms (such as insomnia and agitation) 
in the past are more likely to be on mirtazapine relative 
to sertraline. In the entire cohort and in those aged >25, 
older age was associated with higher probability of being 
prescribed new generation antidepressants, namely—a 
combination of any one SNRI and mirtazapine, a combi-
nation of any one SSRI and mirtazapine, mirtazapine, 
and venlafaxine compared with sertraline. In the entire 
cohort older age was associated with a decreased proba-
bility of being prescribed any one SSRI (tables 4 and 5) 
compared with sertraline.
The results from the analysis in those aged >25 (table 5) 
show increased likelihood of males being on mirtazapine 
compared with females. They also show that, relative to 
sertraline, patients on citalopram or fluoxetine are less 
like to have recorded affective symptoms, patients on 
mirtazapine are more likely to have recorded somatic 
symptoms and patients on fluoxetine were more likely to 
have a recorded suicide attempt in the past 12 months 
relative to those on sertraline. The sensitivity analyses did 
not give rise to any marked difference in findings (see 
online supplementary appendix).
dIsCussIOn
The aim of this study was to ascertain patient demo-
graphic and clinical factors that correlate with different 
antidepressant treatments in patients actively receiving 
secondary mental healthcare for clinical depression. 
While there were no strongly consistent trends across 
all comparison groups or exposures, our results suggest 
that age, past medication and/or psychotherapy receipt 
use and symptom profiles in the past 12 months have 
potentially some influence on antidepressant receipt in 
secondary mental healthcare.
We found that older patients were less likely to be 
using fluoxetine or a combination of two SSRIs relative to 
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sertraline and were more likely to be on other combina-
tions, citalopram, mirtazapine or venlafaxine. Comparable 
to our findings, a study of newly initiated antidepressant 
use in a cohort of over 500 000 war veterans with a diag-
nosis of depression9 found that older patients were less 
likely (RRR 0.70) to have started on fluoxetine than 
sertraline. While we did not seek to collect data on the 
reasoning behind the choices, although this might reflect 
concerns around the longer half-life of fluoxetine in older 
age groups and the lower propensity of sertraline for 
cytochrome-related interactions with coprescribed medi-
cations, the association was less strong in the subgroup 
aged >25, so might be more likely to reflect lower perceived 
risk of treatment-emergent suicidality associated with 
fluoxetine in adolescents and younger adults. Similarly, 
the association of older age with mirtazapine use, individ-
ually or in combination, may reflect perceived likelihood 
of sedation and weight gain—considered problematic 
in younger patients but potentially advantageous (when 
taken at night) in late life depression. On the other hand, 
the higher use of mirtazapine (compared with sertraline) 
in men compared with women may reflect lower inci-
dence of sexual dysfunction side effects.30 Of interest, we 
found no substantial variation in use by ethnicity, marital 
status or neighbourhood socioeconomic status, once age 
and gender had been accounted for, suggesting little 
evidence of socially determined variation in prescribing.
Considering past medication use, antipsychotic, mood 
stabiliser or antidepressant use in the previous 12 months 
was associated with a higher likelihood of the co-occur-
rence of SNRI with mirtazapine during the observation 
period, and mood stabiliser use was also predictive of 
venlafaxine compared with sertraline use. The SNRI–
mirtazapine group were also more likely to have been 
referred for primary care based psychotherapy (the UK’s 
IAPT service model). As this secondary care cohort is 
likely to have an over-representation of individuals with 
some resistance to first-line antidepressant treatment, 
it may follow that these individuals were on other treat-
ment regimens in the past and that newer antidepressant 
regimens were being prescribed in the context of higher 
levels of treatment resistance. However, it is hard to 
define, and therefore identify, patients who are resistant 
to antidepressant treatment especially from naturalistic 
clinical databases, so conclusions can only be tentative.
Considering clinical features, suicidal ideation and 
past suicide attempts were not significantly associated 
with different antidepressant use overall; however, past 
suicide attempt was associated with an increased like-
lihood of fluoxetine compared with sertraline receipt 
in patients aged >25 which, as discussed above for age 
effects, may reflect the evidence collated from meta-anal-
yses of randomised controlled trials and observation 
studies where fluoxetine has been shown to carry reduced 
risk of emergent suicidal behaviour in adults compared 
with children and adolescents.31–33 Those with affective 
symptoms recorded were less likely to be on citalopram 
or fluoxetine than sertraline, while those with somatic 
symptoms were more likely to be on mirtazapine, associ-
ations which persisted in the cohort aged >25. Clinician 
prescribing preference may be influenced by perceived 
therapeutic actions or perceived risk of adverse drug 
events, or both. For example, the somatic symptoms of 
poor appetite and insomnia may increase the likelihood 
of a medication such as mirtazapine being prescribed 
because of recognised propensity to sedation and weight 
gain. There is some evidence to suggest citalopram may 
induce cardiotoxicity in overdose34; however, apart from 
clinical guidelines on when to prescribe antidepres-
sants studies are rarely conducted to assess the associa-
tion singular drugs with depressive symptoms are being 
prescribed.35
As mentioned, there has been very little previous 
research into factors associated with different antidepres-
sant treatments for depression, particularly in secondary 
care. Improved knowledge in this area is important for 
several reasons. First, it is helpful to understand factors 
potentially influencing prescribing behaviour to assess 
the impact of guidelines and to describe variations 
beyond guidelines. From our observations here, the rela-
tive lack of covariates consistently associated with anti-
depressant use suggests prescribing based on individual 
experiences after patient–clinician communication, 
consistent with national guidelines emphasising patient–
clinician communication.35 However, findings suggestive 
of prescribing motivations derived from observational 
data of this nature need further qualitative studies for 
confirmation. Second, while variations in prescribing 
may reflect potentially problematic non-evidence-based 
behaviour, it might also highlight novel patterns arising 
from clinical experience which need to be noted and 
assessed further to improve the evidence base. Early 
detection of adverse or unexpectedly beneficial, effects 
is an example of these indications of how antidepressants 
are being used for treatment in secondary care is more 
realistic than research from pharmaceutical trials. Our 
findings suggest that there are certain antidepressants 
that are avoided in certain clinical scenarios; for example, 
patients previously described as having symptoms in the 
‘affective’ category were less likely to be receiving citalo-
pram or fluoxetine compared with sertraline. There is a 
suggestion from the results that newer generation antide-
pressants are used to treat more severe depression which 
may indicate greater clinician-perceived tolerability and/
or lower toxicity and/or lower propensity to interact with 
other coprescribed medication.29 35
The results should be interpreted with study limitations 
in mind. First, using antidepressant data in a 6-month 
window limited sample sizes for analysis, and inaccurate 
measures of exposure status (eg, the use of area-level 
rather than individual-level socioeconomic status) might 
have reduced the likelihood of identifying underlying 
associations. Second, the study is close to cross-sectional 
design, since there may have been co-occurrence of expo-
sures and outcomes in the prior 12-month observation 
period; therefore, direct causal relationships cannot be 
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conclusively inferred. Third, the duration of the antide-
pressant treatment during the observation period was 
not known, so some patients will have been new users of 
antidepressants identified, while others may have been 
using the antidepressant(s) for much longer periods of 
time; similarly, where there was co-occurrence of two anti-
depressants during the time period evaluated, it was not 
possible to distinguish a switch from one agent to another 
from coprescribing of the two agents. Fourth, the results 
of the study cannot assumed to be generalisable to all 
patients in secondary mental healthcare settings due to 
the social and ethnic diversity found in Southeast London 
from where this sample was drawn; in addition, the focus 
of the study was on antidepressant use in people with 
a depressive disorder diagnosis and being reviewed in 
secondary mental healthcare, so findings cannot assumed 
to generalise to antidepressant use in other circumstances 
or for other indications. Finally, we could only investigate 
factors that were available to us in the current dataset. 
The literature reports various clinical covariates,8 patient 
demographics,9 medication use,36 clinician characteris-
tics3 and clinical location8 9 as factors involved for anti-
depressant prescription in secondary mental healthcare 
settings. We could not capture all these factors in our 
analysis.
Limitations notwithstanding there are key strengths to 
this paper. To our knowledge, this is the first study profiling 
antidepressant use in a cohort of patients receiving treat-
ment for depression in a secondary mental healthcare 
setting in the UK. Although from a single site, the use of 
health records data provides a more generalisable sample 
than would be possible through a conventional cohort 
design involving de novo interviews, let alone through the 
even more selected samples in clinical trials. In addition, 
the data included constructs such as depressive symp-
toms that are not usually available in administrative ‘big’ 
data, taking advantage of a suite of recently developed 
text mining algorithms to capture a greater depth of data 
from free-text fields, circumventing the usual restriction 
of analysed data to those recorded in structured fields. 
The findings have the potential to inform clinical practice 
within this clinical setting. Knowledge of factors involved 
in antidepressant prescription could be used to audit clin-
ical practices and inform whether the clinical practices 
are benefiting patient treatment outcomes.37 However, 
further qualitative work is definitely indicated to identify 
and highlight processes involved in clinician selection of 
antidepressant treatment. Continual monitoring of treat-
ment choices in this cohort may contribute to providing 
optimal care for secondary care patients and there may 
be scope for further quantitative evaluation across a wider 
range of services, and evaluating longer term outcomes 
associated with different treatment decisions.
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